1. Berberine impairs coxsackievirus B3‐induced myocarditis through the inhibition of virus replication and host pro‐inflammatory response
- Author
-
Maolin Wang, Ying Bai, Qian Dai, Hua Yu, Halei Sheng, Lu Jiang, Kebin Zhang, Xiaomei He, Jiang Yu, and Jin Peng
- Subjects
Male ,Myocarditis ,Viral Myocarditis ,Berberine ,viruses ,Coxsackievirus Infections ,Pharmacology ,Virus Replication ,Antiviral Agents ,HeLa ,Mice ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,In vivo ,Virology ,medicine ,Animals ,Humans ,cardiovascular diseases ,030212 general & internal medicine ,Research Articles ,Inflammation ,Mice, Inbred BALB C ,biology ,Plant Extracts ,Alkaloid ,virus diseases ,Heart ,musculoskeletal system ,medicine.disease ,biology.organism_classification ,Enterovirus B, Human ,viral myocarditis ,Disease Models, Animal ,Infectious Diseases ,chemistry ,Viral replication ,Coxsackievirus b3 ,anti‐CVB3 activity ,cardiovascular system ,coxsackievirus B3 ,030211 gastroenterology & hepatology ,Research Article ,HeLa Cells - Abstract
Berberine (BBR), an isoquinoline alkaloid isolated from Rhizoma coptidis, is reported to possess antiviral activity. Our previous study has shown that BBR alleviates Coxsackievirus B3 (CVB3) replication in HeLa cells. However, the anti-CVB3 activity of BBR is still unclear in vivo. In this study, we explored the effect of BBR on CVB3-induced viral myocarditis in mice. These results demonstrated a beneficial effect of BBR on alleviating CVB3-induced myocarditis in vivo, which sheds new light on the utility of BBR as a therapeutic strategy against CVB3-induced viral myocarditis. This article is protected by copyright. All rights reserved.
- Published
- 2020